Implications of antiviral resistance of influenza viruses.
Monto
Arnold S
AS
D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D005060:Europe; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification; D053122:Influenza A Virus, H3N2 Subtype / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification; D053124:Influenza A Virus, H5N1 Subtype / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification; D009980:Influenza A virus / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D007251:Influenza, Human / Q000188:drug therapy* / Q000821:virology*; D007564:Japan; D020125:Mutation, Missense; D009439:Neuraminidase / Q000235:genetics; D014481:United States; D014764:Viral Proteins / Q000235:genetics
D000998:Antiviral Agents; D014764:Viral Proteins; C487630:NA protein, influenza A virus; D009439:Neuraminidase